Postpartum Depression: Identification and Treatment in the Clinic Setting

Emily B Kroska; Zachary N Stowe

doi:10.1016/j.ogc.2020.05.001

Back

Postpartum Depression: Identification and Treatment in the Clinic Setting

Journal article

Peer reviewed

Postpartum Depression: Identification and Treatment in the Clinic Setting

Emily B Kroska and Zachary N Stowe

Obstetrics and gynecology clinics of North America, Vol.47(3), pp.409-419

09/2020

DOI: 10.1016/j.ogc.2020.05.001

PMID: 32762926

View Online

Abstract

Perinatal care, including the management of mental health issues, often falls under the auspices of primary care providers. Postpartum depression (PPD) is a common problem that affects up to 15% of women. Most women at risk can be identified before delivery based on psychiatric history, symptoms during pregnancy, and recent psychosocial stressors. Fortunately, there have been a variety of treatment studies using antidepressants, nonpharmacologic interactions, and most recently, allopregnanolone (Brexanolone) infusion that have shown benefits. The most commonly used screening scale, Edinburgh Postnatal Depression Scale, a 10-item self-rated scale, has been translated into a variety of languages.

Adult

Antidepressive Agents - therapeutic use

beta-Cyclodextrins - therapeutic use

Depression, Postpartum - diagnosis

Depression, Postpartum - drug therapy

Depression, Postpartum - epidemiology

Depression, Postpartum - therapy

Drug Combinations

Female

Humans

Infant

Mass Screening

Neurosteroids - therapeutic use

Perinatal Care

Postpartum Period

Pregnancy

Pregnanolone - therapeutic use

Prevalence

Psychiatric Status Rating Scales

Psychotherapy - methods

Risk Factors

Serotonin Uptake Inhibitors - therapeutic use

Surveys and Questionnaires

Details

Title: Subtitle: Postpartum Depression: Identification and Treatment in the Clinic Setting
Creators: Emily B Kroska - Department of Psychological and Brain Sciences, University of Iowa, W311 Seashore Hall, Iowa City, IA 52242, USA
Zachary N Stowe - Department of Psychiatry, University of Wisconsin-Madison, 6001 Research Park Boulevard, Madison, WI 53719, USA. Electronic address: zstowe@wisc.edu
Resource Type: Journal article
Publication Details: Obstetrics and gynecology clinics of North America, Vol.47(3), pp.409-419
DOI: 10.1016/j.ogc.2020.05.001
PMID: 32762926
ISSN: 0889-8545
eISSN: 1558-0474
Grant note: DOI: 10.13039/100004330, name: GlaxoSmithKline; DOI: 10.13039/100004319, name: Pfizer; name: Wyeth Corporations; DOI: 10.13039/100008897, name: Janssen Pharmaceuticals; DOI: 10.13039/100014605, name: Sage Therapeutics; DOI: 10.13039/100000002, name: National Institutes of Health; DOI: 10.13039/100000030, name: Centers for Disease Control and Prevention
Language: English
Date published: 09/2020
Academic Unit: Psychological and Brain Sciences
Record Identifier: 9984213394902771

Metrics

85 Record Views

71 Times Cited - Web of Science

See more details